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With interest we read the review by Levy et al. [1] that
provides a thorough overview of current and future
therapies aiming to treat vasoplegia, an ubiquitous
phenomenon in shock. In their work, the authors dedi-
cated a section to the novel adrenomedullin (ADM)-bind-
ing antibody adrecizumab, which is mentioned as an
ADM blocking compound in the section title. Recently
published studies demonstrate that blocking of ADM does
not accurately describe adrecizumab’s mechanism of ac-
tion, though.
In contrast to what is often intuitively assumed, not all
antibodies completely inhibit the activity of their targets.
The extent of signaling inhibition can vary greatly, de-
pending on the epitope to which the antibodies bind and
other factors, such as antibody concentrations. In con-
trast to C-terminus binding anti-ADM antibodies which
completely inhibit ADM signaling, antibodies against the
N-terminus of ADM, including the humanized monoclo-
nal antibody adrecizumab, only marginally inhibit ADM
activity, despite their high affinity and even when applied
in vast molar excess over ADM [2].
Interestingly, animal and human data reveal a strong,
dose-dependent increase of plasma ADM concentrations
upon adrecizumab infusion [3, 4], which cannot be ex-
plained by increased production of ADM. A mechanistic
explanation for this occurrence was recently proposed
[5]. Excess antibody that remains in the circulation is
thought to drain ADM from the interstitium into the
circulation, since ADM is small enough to cross the
endothelial barrier, whereas the antibody is not. While
adrecizumab only partially inhibits ADM signaling, the
strong concentration increase of ADM (complexed with
adrecizumab) in the circulation is thought to result in an
overall “net” increase of ADM activity on endothelial
cells, augmenting endothelial barrier stabilizing effects,
while decreased concentrations of ADM in the intersti-
tium reduce vasodilatory effects on vascular smooth
muscle cells. The combination of attenuation of both
endothelial leakage and vasodilation likely represents the
therapeutic potential of adrecizumab. This hypothesis
fits well with previous studies that showed beneficial ef-
fects of ADM agonists in animal models of shock, while
complete inhibition of ADM did not improve outcome.
As is mentioned by the authors, a proof-of-concept
and dose-finding phase II study with adrecizumab is
currently ongoing in patients with septic shock and ele-
vated levels of ADM (ClinicalTrials.gov identifier
NCT03085758). This trial incorporates a number of in-
novative features such as a novel composite efficacy end-
point and biomarker-guided patient selection (enrolment
based on bio-ADM level), making it one of the first per-
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